Slide 1: Immatics Corporate Presentation September 11, 2023
© Immatics. Not for further reproduction or distribution. Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation September 11, 2023
Slide 2: Forward-Looking Statement
Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their resp
Slide 3: Building a Leading TCR Therapeutics Company
Therapeutic Opportunity Potential for addressing large patient populations with high prevalence targets in solid tumors Two Clinical - Stage Modalities Pipeline of TCR - T and TCR Bispecific product candidates in clinical & preclinical development Building a Leading TCR Therapeutics Company 3 Intro
Slide 4: Our Near-Term Focus – Clinical Development of Lead Assets
4 Three IMA203 Ph1b cohorts • IMA203 monotherapy • Checkpoint combo • IMA203CD8 monotherapy Next update on all three IMA203 cohorts and clinical development path for PRAME TCR - T monotherapy towards registration - directed trials is planned for 4Q 2023 ACTengine® IMA203 (PRAME) Advance ongoing Phas
Slide 5: Our TCR-based Approaches Leverage the Full Target Space
Our TCR - based Approaches Leverage the Full Target Space beyond the Cancer Cell Surface 5 Intro
Slide 6: Two Distinct TCR-based Therapeutic Modalities in Clinical Development
Two Distinct TCR - based Therapeutic Modalities in Clinical Development 6 Differentiated positioning of ACTengine® vs. TCER® based on patient population and medical need Intro 1 Interim data update from the ACTengine® IMA203 TCR - T monotherapy Phase 1b Cohort A (published May 02, 2023) with a 64% (
Slide 7: Our Pipeline of TCR-based Adoptive Cell Therapies and Bispecifics
Modality Product Candidate Target Preclinical Phase 1a 1 Phase 1b 1 Phase 2 Phase 3 Autologous ACT ACTengine ® IMA203 PRAME ACTengine® IMA203CD8 PRAME ACTengine® IMA204 COL6A3 Multiple programs Undisclosed Allogeneic ACT γδ T cells ACTallo® IMA30x Undisclosed Multiple programs Undisclosed Bispecific
Slide 8: Immatics & Moderna – Strategic Cross-platform R&D Collaboration
Immatics & Moderna – A Strategic Cross - platform R&D Collaboration Combining Immatics’ Target and TCR Platforms with Moderna’s mRNA Technology 8 TCER® mRNA Approach Development of mRNA - enabled in vivo expressed half - life extended TCER® molecules targeting cancer - specific HLA - presented pepti
Slide 9: Strategic Collaborations
Strategic Collaborations Synergistic Expertise that Can Foster Transformative Innovations across Various Modalities Research collaboration to develop bispecific immunotherapies $54 M upfront, up to $550 M aggregated milestone payments per program, up to double - digit tiered royalties; Co - promotio
Slide 10: Potential for Large Patient Populations across Multiple Solid Cancers
Potential for Large Patient Populations across Multiple Solid Cancers 10 Uterine Carcinoma – 100% Uterine Carcinosarcoma – 100% Sarcoma Subtypes – up to 100% Cut. Melanoma – 95% Uveal Melanoma 1 – 90% Ovarian Carcinoma – 80% Squamous NSCLC – 65% TNBC – 60% Small Cell Lung Cancer – 55% Kidney Carcino
Slide 11: Realizing the Full Multi-Cancer Opportunity of PRAME
Realizing the Full Multi - Cancer Opportunity of PRAME ACTengine® IMA203 (TCR - T) and TCER® IMA402 (TCR Bispecific) 11 Indication % PRAME positive patients 1 Uterine Carcinoma Uterine Carcinosarcoma Sarcoma Subtypes Cut. Melanoma Uveal Melanoma 2 Ovarian Carcinoma Squamous NSCLC TNBC Small Cell Lun
Slide 12: ACTengine IMA203 – Targeting PRAME
ACTengine® IMA203 – TCR - T Targeting PRAME 12
Slide 13: ACTengine IMA203 Targeting PRAME – Mechanism of Action
ACTengine® IMA203 Targeting PRAME – Mechanism of Action Immatics’ Leading TCR - T Approach 13 IMA203
Slide 14: Key Pillars of Developing a Successful Product Candidate
Key Pillars of Developing a Successful TCR - T Product Candidate Summary of Interim Update on IMA203 TCR - T Phase 1b Cohort A as of April 2023 14 Safety Anti - Tumor Activity Durability Product Quality Broad Reach Manageable tolerability at doses as high as ~9x10 9 TCR - T cells High rate of object
Slide 15: The Multi-Cancer Opportunity of PRAME
The Multi - Cancer Opportunity of PRAME One of the Most Promising Solid Tumor Targets for TCR - based Therapies Known To Date 15 High prevalence High target density Homogeneous expression “Clean” expression profile Clinical proof - of - concept s qNSCLC Ovarian Cancer PRAME fulfills all properties o
Slide 16: ACTengine IMA203 Monotherapy – Patient Flow
ACTengine® IMA203 TCR - T Monotherapy – Patient Flow 16 HLA - A*02 Testing Blood sample; Central lab Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase Manufacturing by Immatics Infusion of ACTengine® IMA203 TCR - T Product Lymphodepletion * Target Profiling Fresh Tu
Slide 17: ACTengine IMA203 Phase 1b Design
ACTengine® IMA203 TCR - T Phase 1 Design Focus on IMA203 TCR - T Monotherapy Investigated in Cohort A 17 17 Cohort A Phase 1b Cohort A Interim Update on 11 patients » Focus on generation of safety data » D e - prioritized in the last - line setting, investigation of combination as a front - line the
Slide 18: Phase 1b Cohort A Patient and Product Characteristics
N=11 ACTengine® IMA203 TCR - T Monotherapy – Phase 1b Cohort A Patient and Product Characteristics 18 Data cut - off Apr 04, 2023 Heavily pre - treated, metastatic last - line patients that have exhausted all available standard of care treatments 1 Including ovarian cancer patient A - DL5 - 04 who e
Slide 19: Most Frequent Adverse Events – Phase 1b Cohort A
Most Frequent Adverse Events – Phase 1b Cohort A (N=11) Manageable Treatment - emergent Adverse Events (TEAEs) • Expected cytopenia (Grade 1 - 4) associated with lymphodepletion in all patients • Low - moderate cytokine release syndrome (CRS) in 91% (10/11) of patients • 45% (5/11) of patients had G
Slide 20: Best Overall Response – Phase 1b Cohort A
20 Best Overall Response – Phase 1b Cohort A Deep Objective Responses Independent of Tumor Type 1 Ovarian cancer patient A - DL5 - 04 erroneously received one dose of nivolumab and is part of intent - to - treat population (shown here) but not per - protocol population ; 2 Initial ORR: Objective res
Slide 21: Response over Time – Phase 1b Cohort A
Response over Time – Phase 1b Cohort A Durable Partial Responses 9+ Months after IMA203 TCR - T Treatment 21 ** Ovarian cancer patient A - DL 5 - 04 erroneously received one dose of nivolumab and is part of intent - to - treat population (shown here) but not per - protocol population ; 1 Duration of
Slide 22: Biological Data Consistent with Clinical Data
Biological Data Consistent with Clinical Data IMA203 TCR - T Levels and Tumor Infiltration across Patients in Phase 1a and Phase 1b Cohort A 22 IMA203 T cells found in all evaluable tumor tissues, level of infiltration associated with objective responses 1 Increased levels of IMA203 T cells in the b
Slide 23: Favorable Product Characteristics and High Levels in Patients
Favorable TCR - T Product Characteristics and High TCR - T Levels in Patients Manufacturing Improvements Implemented in Phase 1b Enhance Key Features of the Cell Product 23 Manufacturing success rate of 94% to reach provisional RP2D ** Mean cell d ose infused in 11 patients in Phase 1b Cohort A was
Slide 24: Responses above PRAME RNA Threshold Independent of Tumor Type
Responses above Immatics’ PRAME RNA Threshold Independent of Tumor Type Highlighting Tumor Types (left) and Type of Best Overall Response (right) – Phase 1b Cohort A 24 Mann - Whitney U test, p=0.23; PD: Progressive Disease; SD: Stable Disease; PR: Partial Response; cPR : Confirmed Partial Response;
Slide 25: Potential of IMA203 in Additional Solid Cancer Indications
Potential of IMA203 in Additional Solid Cancer Indications Based on PRAME Expression in IMA203 TCR - T Responders – Phase 1b Cohort A 25 Immatics’ proprietary mass spectrometry - guided mRNA threshold 100% 100% 95% 100% 90% (50% 2 ) 80% 60% 65% 25% % PRAME - positive patients 1 PRAME target expressi
Slide 26: Summary of Phase 1b Cohort A Interim Data Update
ACTengine® IMA203 TCR - T Monotherapy Targeting PRAME Summary of Phase 1b Cohort A Interim Data Update • Manageable tolerability with no high - grade CRS, no ICANS in 11 patients in Cohort A 1 • Objective responses observed in heavily pre - treated last - line solid cancer patients including checkpo
Slide 27: ACTengine IMA203 Development Strategy
Immatics’ ACTengine® IMA203 TCR - T Development Strategy Two - Pillared Strategy 27 Objective: Expand development to other cancer types • Signal finding in other cancer types with a broad patient reach, such as ovarian cancer, uterine cancer, lung cancer, breast cancer, head and neck cancer GO BROAD
Slide 28: ACTengine IMA203 Product Manufacturing
ACTengine® IMA203 TCR - T Product Manufacturing Enhancing Manufacturing Process and Capabilities Leukapheresis Rapid Manufacturing Process 1 week Expedited QC Release Testing 1 week Infusion - ready Manufacturing of ACTengine® IMA203 TCR - T & other future autologous /allogeneic candidates Expected
Slide 29: IMA203 Has the Potential to Reach a Large Patient Population
Selected Indications Incidence R/R Incidence PRAME Positive Patient Population Based on R/R Incidence; PRAME and HLA - A*02:01+ Cut. Melanoma 99,800 7,700 95% 2,999 Uveal Melanoma 1,500 800 90% 295 Ovarian Carcinoma 19,900 12,800 80% 4,198 Uterine Carcinoma 62,700 10,700 100% 4,387 Uterine Carcinosa
Slide 30: ACTengine IMA203CD8 – Next-generation
ACTengine® IMA203CD8 – Next - generation TCR - T Building on First - Gen IMA203 Success to Further Improve Anti - Tumor Activity • Engagement of CD4 T cells by CD8 co - transduction reported to boost anti - tumor activity in TCR - T trials • Recent data from leukaemia patients treated with CAR - T s
Slide 31: IMA203CD8 – Preclinical Assessment of Anti-Tumor Efficacy
ACTengine® IMA203CD8 – Preclinical Assessment of Anti - Tumor Efficacy Functional CD4 T cells Mediate Longer Anti - Tumor Activity than CD8 T cells in vitro 31 0 50 100 150 200 250 300 350 400 450 0.0 0.5 1.0 1.5 2.0 CD8 Hours after Coculture T u m o r f o l d g r o w t h 0 50 100 150 200 250 300 35
Slide 32: ACTengine IMA204 – Targeting COL6A3 Exon 6
ACTengine® IMA204 – TCR - T Targeting COL6A3 Exon 6 32
Slide 33: ACTengine IMA204 First-in-Class Targeting Tumor Stroma
ACTengine® IMA204 First - in - Class TCR - T Targeting Tumor Stroma Key Features 33 HLA - A*02 - presented peptide derived from COL6A3 exon 6 Naturally and specifically presented on tumors at high target density 1 : 100 - 700 copies/cell Novel tumor stroma target identified and validated by XPRESIDE
Slide 34: IMA204 – High Affinity, CD8-independent TCR
ACTengine® IMA204 – High Affinity, CD8 - independent TCR Complete Tumor Eradication in vitro & in vivo 1 by Affinity - enhanced IMA204 TCR CD8 - independent TCR leads to tumor eradication in all mice treated 34 Control IMA204 TCR D7 D16 D22 D29 Affinity maturated CD8 - independent, next - generation
Slide 35: ACTallo – Our Next-generation Off-the-shelf
ACTallo® – Our Next - generation Off - the - shelf TCR - T 35
Slide 36: ACTallo – Immatics' Allogeneic Cell Therapy Approach
ACTallo® – Immatics’ Allogeneic Cell Therapy Approach • Off - the - shelf cell therapy , no need for personalized manufacturing reduced logistics and time to application • Potential for hundreds of doses from one single donor leukapheresis lower cost of goods • Use of healthy donor material prov
Slide 37: Why γδ T cells?
Why γδ T cells? γδ T cells Are Well Suited for an Off - the - shelf Cell Therapy Approach 37 γδ T cells x are abundant in the peripheral blood x show intrinsic anti - tumor activity x naturally infiltrate solid tumors & correlate with favorable prognosis x are HLA - independent, thus do not cause gr
Slide 38: TCER – TCR Bispecifics
8oe Immiatics TCER® — TCR Bispecifics
Slide 39: TCER – Next-generation, Half-Life Extended Bispecifics
TCER® – Immatics ’ Next - generation, Half - Life Extended Bispecifics Proprietary TCER® Format Consisting of Three Distinct Elements 39 High - affinity TCR domains targeting XPRESIDENT® - selected tumor - specific peptide - HLA molecules Low - affinity T cell recruiter against CD3/TCR Fc part for h
Slide 40: TCER – Next-generation, Half-Life Extended Bispecifics
TCER® – Immatics’ Next - generation, Half - Life Extended Bispecifics 40 pHLA targeting TCR x High - affinity (single digit nM ) TCR targeting XPRESIDENT® - selected tumor - specific peptide - HLA molecules x Broad therapeutic window through XPRESIDENT® - guided affinity maturation (>1000x) 1 x Comp
Slide 41: Potency of Our Proprietary TCR Bispecific Format TCER
Potency of Our Proprietary TCR Bispecific Format TCER® 41 • Seven different TCR Bispecific formats were evaluated with a pHLA targeting TCR and the identical T cell recruiting antibody • TCER® format had higher combination of potency and specificity 1 than six alternative TCR Bispecific format desig
Slide 42: TCER Format Designed for Optimized Efficacy and Safety
TCER® Format Is Designed for Optimized Efficacy and Safety Superior Tumor Control Using a Novel, Low - Affinity Recruiter 42 Widely used T cell recruiting Ab (3 variants) medium to high affinity (single to double digit nM ) n = 6 mice/treatment group, n = 10 mice in vehicle group, 2 donors/group Dos
Slide 43: TCER Reduced Target-Unrelated Cytokine Release
TCER® Format Is Designed for Optimized Efficacy and Safety Reduced Target - Unrelated Recruiter - Mediated Cytokine Release using a Low - Affinity Recruiter 43 TCER® Whole blood cytokine release assay N= 3 HLA - A*02 - positive donors N=16 cytokines tested, 4 exemplary cytokines shown
Slide 44: Our TCER Portfolio
Our TCER® Portfolio Broad Pipeline of Next - Gen Half - Life Extended TCR Bispecifics 44 TCER® • PRAME peptide presented by HLA - A*02:01 • Start of clinical trial in Aug 2023, first clinical data expected 2024 IMA402 Potential for addressing different indications and large patient populations with
Slide 45: TCER IMA401 Targeting MAGEA4/8
TCER® IMA401 Targeting MAGEA4/8 Homogeneous Expression, Broad Prevalence and High Copy Number Target 45 MAGEA4 RNA detection in tumor samples (ISH) Indications Target p revalence [%] Squamous non - small cell lung carcinoma 50% Head and neck squamous cell carcinoma 35% Bladder carcinoma 30% Uterine
Slide 46: IMA401 – Anti-Tumor Activity in vitro
TCER® IMA401 (MAGEA4/8) – Assessment of Anti - Tumor Activity in vitro Patient - Derived Tumor Model 46 NSCLC adenocarcinoma : • M ale, Caucasian, age 58, no therapy prior to surgery • Site of origin: lung, differentiation poor • Date of surgery: 1987, Freiburg Medical Center • Volume doubling time:
Slide 47: IMA401 – Pharmacokinetics
47 TCER® IMA401 (MAGEA4/8) – Pharmacokinetics PK Analysis in NOG Mice • Two different PK assays established to ensure functional integrity of protein domains • Terminal half - life in mice: 10 - 11 days pHLA – V L Assay Fc – V L Assay IMA401
Slide 48: Phase 1 Clinical Trial to Evaluate TCER IMA401
Phase 1 Clinical Trial to Evaluate TCER® IMA401 Targeting MAGEA4/8 48 MTD: maximum tolerated dose, RP2D: recommended phase 2 dose; MABEL: minimum anticipated biological effect level; BLRM: Bayesian logistic regression model; 1 P harmacokinetics data assessed throughout the trial might provide an opp
Slide 49: IMA402 Targeting PRAME – Efficacy Assessment in vitro
TCER® IMA402 Targeting PRAME – Efficacy Assessment in vitro Tumor Cell Killing at Low Physiological PRAME Peptide Levels 49 0 20 40 60 80 100 120 140 10 -1 10 0 10 1 10 2 10 3 10 4 10 5 IMA402 [pM] Cytotoxicity [%] ~50 PRAME CpCs 0 0 20 40 60 80 100 120 140 10 -1 10 0 10 1 10 2 10 3 10 4 10 5 IMA402
Slide 50: IMA402 Achieves Durable Tumor Control of Large Tumors in vivo
TCER® IMA402 Achieves Durable Tumor Control of Large Tumors in vivo 50 -29 0 500 1000 1500 2000 2500 0 10 20 30 40 50 60 70 Study day M e d i a n t u m o r v o l u m e [ m m 3 ] Vehicle IMA402 [0.01 mg/kg] IMA402 [0.05 mg/kg] IMA402 [0.25 mg/kg] • Dose - dependent efficacy of IMA402 in cell line - d
Slide 51: Half-life Extended Format of IMA402
Half - life Extended Format of IMA402 Confers Terminal Half - life of >1 Week 51 pHLA – aV L Assay pHLA – aFc Assay • IMA402 shows a terminal serum half - life of ≈ 8 days in mice • IMA402 will be initially dosed weekly in the clinical trial • Dosing frequency may be adapted based on clinical data I
Slide 52: Phase 1/2 Clinical Trial to Evaluate TCER IMA402
Phase 1/2 Clinical Trial to Evaluate TCER® IMA402 Targeting PRAME First Clinical Data Planned in 2024 52 Phase 1: Dose Escalation Phase 2a: Dose Expansion Adaptive design aimed at accelerating dose escalation • Specific indications plus ongoing basket • Combination therapies • Optional dose/applicat
Slide 53: Immatics' Proprietary Target and TCR Discovery Platforms
Immatics’ Proprietary Target and TCR Discovery Platforms 53
Slide 54: True Cancer Targets & Matching Right TCRs
True Cancer Targets & Matching Right TCRs Goal to Maximize Anti - Tumor Activity and Minimize Safety Risks of TCR - based Immunotherapies 54 True Targets via XPRESIDENT® technology platform • are naturally presented on tumor tissues as identified by mass - spec • are absent or presented at only low
Slide 55: Pool of Prioritized Targets – XPRESIDENT Platform
Technology Pool of 200 Prioritized Targets as Foundation for Future Value Generation XPRESIDENT® Target Platform 55 200 Prioritized Targets Grouped in 3 Target Classes: 1. Well known and characterized parent protein (20%) e.g. MAGE family cancer testis antigens 2. Unknown or poorly characterized par
Slide 56: Identification of the Most Relevant Target – MAGEA4/8
Immatics ’ Unique Capability – Identification of the most Relevant Target Example of MAGEA4/8 Peptide Target 56 1 Copy number per tumor cell (CpC) measured on a paired - sample basis by AbsQuant®, i.e. comparing MAGEA4 vs. MAGEA4/A8 peptide pre sentation on same sample, 2 Students paired T test p<0.
Slide 57: Development of the Right TCR – XCEPTOR Technology
Development of the Right TCR – XCEPTOR® Technology TCR Discovery and Engineering for ACT and TCR Bispecifics 57 TCR Bispecifics T cell engaging receptor (TCER®) Adoptive Cell Therapy ACTengine® ACTallo ® • Fast, efficient and highly sensitive discovery of highly specific, natural TCRs • Protein engi
Slide 58: Optimal Target Selection & TCR Specificity for Minimizing Safety Risks
Optimal Target Selection & TCR Specificity for Minimizing Safety Risks Unique Interplay between Technology Platforms Allows Early De - risking for Clinical Development 58 Target peptide presented on tumor cells Selective killing of tumor cells Target peptide presented on normal cells Off - target to
Slide 59: AI Is Where the Data Is – XCUBE
“AI Is Where the Data Is®” Bioinformatics and AI - Platform XCUBE Ρ 59 Data Engineering Development of data warehouses & user interfaces Data Science Development of statistical & machine learning models Data Processing Processing of mass - spec & next - gen sequencing data 1 THERAPEUTIC KNOWLEDGE XP
Slide 60: Robust IP Portfolio
Robust IP Portfolio Immatics’ Patent Estate – Territorial Coverage 60 Cancer targets, TCRs and technology protected by: • 5,800 applications and patents filed in all major countries and regions • >115 patent families • >2,400 granted patents, thereof >550 granted patents in the US Technology
Slide 61: Corporate Information & Milestones
Corporate Information & Milestones 61
Slide 62: Management Team
David Leitner Schuldirektor David Leitner Schuldirektor David Leitner Schuldirektor Harpreet Singh Chief Executive Officer Co - Founder >20 yrs biotech experience Arnd Christ Chief Financial Officer >20 yrs biotech experience ( InflaRx , Medigene , NovImmune , Probiodrug ) Carsten Reinhardt Chief De
Slide 63: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans - Atlantic Organization 63 Houston, Texas ~ 150 FTEs Cell therapy development & manufacturing Munich, Germany ~ 65 FTEs Various operating functions Tübingen, Germany ~ 215 FTEs Target & TCR discovery and TCR Bispecifics developme nt Corporate FTE status as
Slide 64: Appendix
Delivering s the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. www.immatics.com Appendix
Slide 65: IMA203 Monotherapy Tolerability Data – Phase 1b Cohort A
ACTengine® IMA203 TCR - T 1 st Gen Monotherapy Tolerability Data Focus on IMA203 Phase 1b Cohort A – All ≥Grade 3 Adverse Events (N=11) 65 • IMA203 was well tolerated • No Adverse Event ≥Grade 3 was observed with a frequency ≥10% when excluding expected cytopenias associated with lymphodepletion • N
Slide 66: Deep & Durable Responses in Heavily Pre-Treated Patients
Deep & Durable Responses in Heavily Pre - Treated Patients – Phase 1b Cohort A 66 Patient ID Indication No of prior treatment lines Prior treatments Total infused dose TCR - T cells 1 [x10 9 ] BOR BOR (Max % change of target lesions) Comment A - DL5 - 01 Uveal Melanoma 1 ARRY614/Nivolumab 4.16 cPR -
Slide 67: IMA203 Monotherapy Tolerability Data – Phase 1a and 1b
ACTengine® IMA203 TCR - T 1 st Gen Monotherapy Tolerability Data Phase 1a and Phase 1b Cohort A – All ≥Grade 3 Adverse Events (N=39) 67 • IMA203 was well tolerated • No Adverse Event ≥Grade 3 was observed with a frequency ≥10% when excluding expected cytopenias associated with lymphodepletion • No I
Slide 68: Phase 1a and Phase 1b Cohort A – Best Overall Response
Phase 1a and Phase 1b Cohort A – Best Overall Response 68 Confirmed objective responses across a broad spectrum of different tumor types such as cutaneous melanoma, uveal melanoma, head and neck cancer, ovarian cancer, synovial sarcoma * Maximum change of target lesions and RECIST 1.1 BOR at differe
Slide 69: Phase 1a and Phase 1b Cohort A – Responses over Time
Phase 1a and Phase 1b Cohort A – Responses over Time Improved Durability at Higher Dose and in Phase 1b Patients 69 Phase 1a (Dose Escalation) N=27 # Phase 1b (Cohort A) N=11 Best overall response (RECIST1.1) IMA203 # Synovial sarcoma patient (DL 3 ) PD at week 6 not shown as t arget lesions were no
Slide 70: Focus on Melanoma Patients
Focus on Melanoma Patients Phase 1a (DL4 only) and Phase 1b Cohort A Continuous Improvement from Phase 1a to Phase 1b Cohort A 70 Patient Characteristics (n=10) Prior lines of treatment Mean (min, max) 4.5 (1, 7) Previous lines of CPI Mean (Min, Max) 2.6 (1, 4) LDH at baseline >1 x ULN [% of patient
Slide 71: Delivering the Power of T cells to Cancer Patients
Delivering s the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. www.immatics.com